Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $17 from $15 and keeps an Outperform rating on the shares after the ...

Monte Rosa reported that one of its molecular glue degraders had seen a strong response in immune disorders, but another fell ...

So now let's turn to the I&I program starting with MRT-6160 our VAV1 directed molecular glue degrader. And so as you can see on Slide 5, VAV1 is a signaling molecule critical in both T and B cell ...

Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ: GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading.

In lab studies, the orally active drug has been shown to degrade the VAV1 protein expressed in T- and B- cells. VAV1 is thought to be a signalling protein involved in the production of pro ...

Monte Rosa Therapeutics (NASDAQ: GLUE) showcased a promising outlook during its Q4 2024 earnings call, highlighting a robust cash runway projected into 2028. The company maintains a strong ...

Monte Rosa Therapeutics (NASDAQ: GLUE) showcased a promising outlook during its Q4 2024 earnings call, highlighting a robust cash runway projected into 2028. The company maintains a strong financial ...

After studying Biochemistry at the University of Oxford (Somerville College), I joined the MRC’s 4-year PhD program in Molecular Cell Biology at UCL’s LMCB. During my PhD I studied the generation of ...